Executive Summary
The Drug Enforcement Administration (DEA) recently released a proposed rule that would establish a Special Registration process for providers seeking to prescribe Schedules II-V drugs via telemedicine. This process would have far reaching effects on low-income individuals and others who have increasingly relied on telemedicine since the COVID-19 pandemic began, including individuals in rural areas, people with disabilities, and individuals who lack transportation. In these comments to the DEA, NHeLP raised concerns with various specific proposals related to the Special Registration process that would impose new barriers for telemedicine prescribing.
